No price history available.
Key financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | KRWm | 4,490 | 3,786 | 3,415 | 2,489 | 1,428 | 3,339 | N/A | N/A |
| Operating profit | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | KRWm | -7,637 | -7,574 | -9,012 | -7,323 | -13,454 | -13,404 | N/A | N/A |
| EPS reported | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
JLK, Inc., a South Korean enterprise, provides artificial intelligence-powered solutions to aid in patient diagnostics. The company's offerings span both AI medical and AI security applications. Its advanced AI platform delivers real-time, on-site services, integrating effortlessly with hospital infrastructure to fulfill the diagnostic needs of healthcare professionals. JLK's medical segment addresses a diverse array of conditions, supporting their management, treatment, and overall service. This includes a significant focus on neurological disorders like ischemic stroke, hemorrhagic stroke, brain aneurysm, and Alzheimer's disease. Furthermore, the company extends its capabilities to lung diseases, coronary artery disease, prostate cancer, and digital pathology. Formerly known as JLK INSPECTION Co.,Ltd., JLK, Inc. is headquartered in Cheongju, South Korea.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
JLK, Inc., a South Korean enterprise, provides artificial intelligence-powered solutions to aid in patient diagnostics. The company's offerings span both AI medical and AI security applications. Its advanced AI platform delivers real-time, on-site services, integrating effortlessly with hospital infrastructure to fulfill the diagnostic needs of healthcare professionals. JLK's medical segment addresses a diverse array of conditions, supporting their management, treatment, and overall service. This includes a significant focus on neurological disorders like ischemic stroke, hemorrhagic stroke, brain aneurysm, and Alzheimer's disease. Furthermore, the company extends its capabilities to lung diseases, coronary artery disease, prostate cancer, and digital pathology. Formerly known as JLK INSPECTION Co.,Ltd., JLK, Inc. is headquartered in Cheongju, South Korea.